RH Laessig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
RH Laessig has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
S S Ehrmeyer
University of Wisconsin, Madison, WI, USA
8 shared publicationsJ E Leinweber
2 shared publicationsD J Hassemer
1 shared publicationSS Ehrmeyer
1 shared publication- Sharon S. Ehrmeyer
Departments of Pathology and Laboratory Medicine and Population Health Sciences Room 6175
1 shared publication
Latest Publications
- 1 May 2001
- Vol. 307 (1)
Electronic "Quality Control" (EQC): is it just for unit use devices?
- 1 September 1997
- p. 10-3; quiz 34
Point-of-care testing technology. Is quality control still relevant?
- 1 September 1997
- p. 10-3; quiz 34
Point-of-care testing technology. Is quality control still relevant?
- 1 May 1997
- Vol. 43 (5) , 903-907
Quality: The next six months
The eclectic mix of participants in the forum had a surprisingly singular focus when it came to the topic of quality in clinical laboratories. All sensed that the time is right for a transition from laws, rules, and inspections to a true quality-based system. Such a system can achieve the goals, implicit and explicit, that are the rationale for the multiplicity of regulations affecting today's laboratories. A true quality-based system has great potential benefits to laboratories, regulators, and manufacturers, and ultimately to our true customers, the patients. The benefits include lower costs, superior products, and better test results; in short, better patient tare. This transition will be possible only through formation of a ''Quality Alliance,'' composed of those skilled in the ''theory'' of quality-laboratory personnel, manufacturers, and regulators, acting as one to implement the quality system. The Quality Alliance requires a team of individuals with different skills, aligned as one, for the purpose of achieving a common goal. On the basis of views expressed in this Forum, our collective future will be defined by the evolving Quality Alliance, an alliance focused on true quality systems in clinical laboratories.
- 1 May 1997
- Vol. 43 (5) , 903-907
Quality: The next six months
The eclectic mix of participants in the forum had a surprisingly singular focus when it came to the topic of quality in clinical laboratories. All sensed that the time is right for a transition from laws, rules, and inspections to a true quality-based system. Such a system can achieve the goals, implicit and explicit, that are the rationale for the multiplicity of regulations affecting today's laboratories. A true quality-based system has great potential benefits to laboratories, regulators, and manufacturers, and ultimately to our true customers, the patients. The benefits include lower costs, superior products, and better test results; in short, better patient tare. This transition will be possible only through formation of a ''Quality Alliance,'' composed of those skilled in the ''theory'' of quality-laboratory personnel, manufacturers, and regulators, acting as one to implement the quality system. The Quality Alliance requires a team of individuals with different skills, aligned as one, for the purpose of achieving a common goal. On the basis of views expressed in this Forum, our collective future will be defined by the evolving Quality Alliance, an alliance focused on true quality systems in clinical laboratories.
- 1 October 1995
- Vol. 104, S40-9
Regulatory requirements (CLIA '88, JCAHO, CAP) for decentralized testing.
All decentralized testing is regulated according to the Clinical Laboratory Improvement Amendments of 1988. Two organizations, the Joint Commission on Accreditation of Health Care Organizations and the College of American Pathologists, have received deemed status for their voluntary standards from the Health Care Financing Administration. Deemed status means that the organizations' voluntary standards meet or exceed the federal requirements. The decentralized testing sites can exercise several options in determining which organization, and hence which set of standards, will be used to regulate their testing processes. In this article, the authors outline the various regulatory requirements, provide insight into the relationship of each, and offer a framework for decentralized testing sites to follow to meet the requirements.
- 1 October 1995
- Vol. 104, S40-9
Regulatory requirements (CLIA '88, JCAHO, CAP) for decentralized testing.
All decentralized testing is regulated according to the Clinical Laboratory Improvement Amendments of 1988. Two organizations, the Joint Commission on Accreditation of Health Care Organizations and the College of American Pathologists, have received deemed status for their voluntary standards from the Health Care Financing Administration. Deemed status means that the organizations' voluntary standards meet or exceed the federal requirements. The decentralized testing sites can exercise several options in determining which organization, and hence which set of standards, will be used to regulate their testing processes. In this article, the authors outline the various regulatory requirements, provide insight into the relationship of each, and offer a framework for decentralized testing sites to follow to meet the requirements.
- 1 July 1992
- Vol. 116 (7) , 770-6
Health Care Financing Administration's new proficiency testing rules. Use of a statistical approach to predict long-term performance using the categories 'successful,' 'probation,' and 'suspended'.
Under the Clinical Laboratory Improvement Act of 1967 (CLIA-67) and the Medicare Act, the Health Care Financing Administration's proficiency testing rules apply uniformly to all hospital and reference laboratories. We examined the relationship between internal laboratory performance as characterized by bias and coefficient of variation and proficiency testing performance, categorized as "successful," "probation," and "suspended." Under the March 14, 1990, final rule, a laboratory with suspended testing for even one analyte may be required to cease testing in the entire subspecialty, eg, routine chemistry, unless it ceases testing for that analyte. Analyzing this regimen as a Markov process, we obtained the steady-state solution for performance for one to 27 analytes. While 1.1% of laboratories testing for five analytes with internal or day-to-day coefficients of variation at 50% of the CLIA-67 proficiency testing limit would be suspended, 19.5% of laboratories having biases of 50% and coefficients of variation of 33% would be suspended. We conclude that after eight events, there will be an unacceptably high rate of suspensions.
- 1 July 1992
- Vol. 116 (7) , 770-6
Health Care Financing Administration's new proficiency testing rules. Use of a statistical approach to predict long-term performance using the categories 'successful,' 'probation,' and 'suspended'.
Under the Clinical Laboratory Improvement Act of 1967 (CLIA-67) and the Medicare Act, the Health Care Financing Administration's proficiency testing rules apply uniformly to all hospital and reference laboratories. We examined the relationship between internal laboratory performance as characterized by bias and coefficient of variation and proficiency testing performance, categorized as "successful," "probation," and "suspended." Under the March 14, 1990, final rule, a laboratory with suspended testing for even one analyte may be required to cease testing in the entire subspecialty, eg, routine chemistry, unless it ceases testing for that analyte. Analyzing this regimen as a Markov process, we obtained the steady-state solution for performance for one to 27 analytes. While 1.1% of laboratories testing for five analytes with internal or day-to-day coefficients of variation at 50% of the CLIA-67 proficiency testing limit would be suspended, 19.5% of laboratories having biases of 50% and coefficients of variation of 33% would be suspended. We conclude that after eight events, there will be an unacceptably high rate of suspensions.
- 1 June 1992
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 38 (6) , 895-903
Intralaboratory Performance Requirements Necessary to Pass Proficiency Testing: CAP-1990 vs CLIA-1967 (March 14, 1990) Formats Compared
The pre-1990 College of American Pathologists' (CAP) Proficiency Testing (PT) program used a two samples per analyte/four challenges per year format with performance or pass-fail grading criteria determined by the program. On Jan. 1, 1991, the Clinical Laboratory Improvement Act of 1967 (CLIA-67) final rules (March 14, 1990) mandated a revised PT format of five samples per analyte/four challenges per year, with the regulations specifying minimum performance criteria. Extending our previous analysis, we compare the maximum permissible intralaboratory imprecision at low bias compatible with passing external PT in the former CAP and current CLIA-67 formats. If a laboratory is able to reduce its internal coefficient of variation (CV) to less than 44% of the PT criterion for each analyte, its overall chance of adverse action for any of the 27 routine chemistry analytes specified in CLIA-67 will be less than 1% in a two-year (eight PT challenges or events) period. Consideration of actual interlaboratory CVs from CAP surveys suggest that a reduction of this magnitude may be difficult for the analytes total cholesterol and blood urea nitrogen, where intralaboratory imprecision comparable with the group standard deviation (SD) from 1990 CAP surveys would yield individual adverse action (PT failure) rates of 5% and 1%, respectively. Five other analytes have CLIA-67 performance limits dangerously close to CAP interlaboratory CVs.
- 1 June 1992
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 38 (6) , 895-903
Intralaboratory Performance Requirements Necessary to Pass Proficiency Testing: CAP-1990 vs CLIA-1967 (March 14, 1990) Formats Compared
The pre-1990 College of American Pathologists' (CAP) Proficiency Testing (PT) program used a two samples per analyte/four challenges per year format with performance or pass-fail grading criteria determined by the program. On Jan. 1, 1991, the Clinical Laboratory Improvement Act of 1967 (CLIA-67) final rules (March 14, 1990) mandated a revised PT format of five samples per analyte/four challenges per year, with the regulations specifying minimum performance criteria. Extending our previous analysis, we compare the maximum permissible intralaboratory imprecision at low bias compatible with passing external PT in the former CAP and current CLIA-67 formats. If a laboratory is able to reduce its internal coefficient of variation (CV) to less than 44% of the PT criterion for each analyte, its overall chance of adverse action for any of the 27 routine chemistry analytes specified in CLIA-67 will be less than 1% in a two-year (eight PT challenges or events) period. Consideration of actual interlaboratory CVs from CAP surveys suggest that a reduction of this magnitude may be difficult for the analytes total cholesterol and blood urea nitrogen, where intralaboratory imprecision comparable with the group standard deviation (SD) from 1990 CAP surveys would yield individual adverse action (PT failure) rates of 5% and 1%, respectively. Five other analytes have CLIA-67 performance limits dangerously close to CAP interlaboratory CVs.
- 1 April 1988
- Vol. 112 (4) , 329-33
Proficiency testing programs--promises, progress, and problems. A 40-year prospective.
Proficiency testing as a means of interlaboratory improvement is over 40 years old. Proficiency testing as a tool of the regulatory process is nearly 20. While successful, ie, the quality of laboratory work in the United States has improved significantly during the past 40 years, this union of regulation and education continues to be a marriage of unequals. Clearly, those who started the professional laboratory community on the road to interlaboratory proficiency testing envisioned a promise of improved quality. The promise is fulfilled; even on an interlaboratory basis, the quality of work (precision) approaches or even exceeds the clinicians' requirements for medically useful data. Major problems continue to exist: the prospect of regulating a vast population of "physicians' office laboratories" presents new challenges for program providers, and as methodologies in laboratories have improved, some of the long-held systems of grading and performance evaluation are beginning to fail. The failure is not one of intent, logistics, or statistics. Proficiency testing, as a fine sharp tool, is corrupted when applied in a situation in which it is ill suited to perform. New knowledge will renew the promise and allow the professional, clinical laboratory community to progress.
- 1 April 1988
- Vol. 112 (4) , 329-33
Proficiency testing programs--promises, progress, and problems. A 40-year prospective.
Proficiency testing as a means of interlaboratory improvement is over 40 years old. Proficiency testing as a tool of the regulatory process is nearly 20. While successful, ie, the quality of laboratory work in the United States has improved significantly during the past 40 years, this union of regulation and education continues to be a marriage of unequals. Clearly, those who started the professional laboratory community on the road to interlaboratory proficiency testing envisioned a promise of improved quality. The promise is fulfilled; even on an interlaboratory basis, the quality of work (precision) approaches or even exceeds the clinicians' requirements for medically useful data. Major problems continue to exist: the prospect of regulating a vast population of "physicians' office laboratories" presents new challenges for program providers, and as methodologies in laboratories have improved, some of the long-held systems of grading and performance evaluation are beginning to fail. The failure is not one of intent, logistics, or statistics. Proficiency testing, as a fine sharp tool, is corrupted when applied in a situation in which it is ill suited to perform. New knowledge will renew the promise and allow the professional, clinical laboratory community to progress.
- 1 April 1988
- Vol. 112 (4) , 444-8
An evaluation of the ability of proficiency testing programs to determine intralaboratory performance. Peer group statistics vs clinical usefulness limits.
Proficiency testing programs use two basic approaches for evaluating participant performance: (1) state-of-the-art data based on the interlaboratory group mean and group SD, or the 1(2)s rule; and (2) fixed limits or assigned intervals around the true value. Our previously described computer model emulates the state-of-the-art approach by simulating the performance of 401 laboratories in interlaboratory proficiency testing programs using the 1(2)s rule. The use of fixed limits to evaluate laboratory performance can be simulated by simple probability calculations. We compare the 1(2)s rule and fixed limits on the basis of their ability to identify actual intralaboratory performance correctly using efficiency. In both cases, the maximum efficiency never exceeds 91% and depends on population SD or fixed limit, specific requirements for medical usefulness, and the prevalence (10%) of poorly performing laboratories in the proficiency testing population. This calculation gives some insight into why neither of these approaches adequately differentiates between good and bad intralaboratory performance.
- 1 April 1988
- Vol. 112 (4) , 444-8
An evaluation of the ability of proficiency testing programs to determine intralaboratory performance. Peer group statistics vs clinical usefulness limits.
Proficiency testing programs use two basic approaches for evaluating participant performance: (1) state-of-the-art data based on the interlaboratory group mean and group SD, or the 1(2)s rule; and (2) fixed limits or assigned intervals around the true value. Our previously described computer model emulates the state-of-the-art approach by simulating the performance of 401 laboratories in interlaboratory proficiency testing programs using the 1(2)s rule. The use of fixed limits to evaluate laboratory performance can be simulated by simple probability calculations. We compare the 1(2)s rule and fixed limits on the basis of their ability to identify actual intralaboratory performance correctly using efficiency. In both cases, the maximum efficiency never exceeds 91% and depends on population SD or fixed limit, specific requirements for medical usefulness, and the prevalence (10%) of poorly performing laboratories in the proficiency testing population. This calculation gives some insight into why neither of these approaches adequately differentiates between good and bad intralaboratory performance.
- 1 June 1986
- Vol. 6 (2) , 317-27
Quality control and quality assurance.
The office laboratory's need for quality is no different from that of any other clinical laboratory. If patients are to receive the benefit of physician's office testing, reliable, high-quality laboratory results are essential. To achieve this, the physician's office laboratory must have an adequate quality assurance program. Several fundamental components of such a program have been addressed in this article: procedure manuals, record-keeping, maintenance logs, quality control charts, participation in proficiency testing, and laboratory inspection. If your state's regulations do not yet require these activities in the physician's office laboratory, they soon will! A successful laboratory's quality assurance program will provide the following assurances. (1) Quality practices are established and followed by all personnel involved with the testing in the laboratory. (2) The technologist performing the test will know when systems and instruments are working properly and the patients' results are reliable. (3) High-quality information needed by the physician interpreting or evaluating patient laboratory results will be generated. (4) A set of written records is available demonstrating to the inspector that uniform and acceptable protocols have been established and are practiced in the laboratory. One short article cannot provide all the specifics for a laboratory's quality assurance program. The manufacturers and suppliers of instruments and reagents should be able to provide support in the following areas: calibration, type of controls to be used, development of a control chart, required maintenance procedures, establishment of accuracy and precision, and troubleshooting. If they cannot or will not, your laboratory should, perhaps, consider an alternative vendor to supply instrumentation and/or reagents. Additionally, resources such as the professional organizations, consultants, other clinical laboratories, and the inspectors or certifying agencies should also be considered in developing a comprehensive quality assurance program.
- 1 June 1986
- Vol. 6 (2) , 317-27
Quality control and quality assurance.
The office laboratory's need for quality is no different from that of any other clinical laboratory. If patients are to receive the benefit of physician's office testing, reliable, high-quality laboratory results are essential. To achieve this, the physician's office laboratory must have an adequate quality assurance program. Several fundamental components of such a program have been addressed in this article: procedure manuals, record-keeping, maintenance logs, quality control charts, participation in proficiency testing, and laboratory inspection. If your state's regulations do not yet require these activities in the physician's office laboratory, they soon will! A successful laboratory's quality assurance program will provide the following assurances. (1) Quality practices are established and followed by all personnel involved with the testing in the laboratory. (2) The technologist performing the test will know when systems and instruments are working properly and the patients' results are reliable. (3) High-quality information needed by the physician interpreting or evaluating patient laboratory results will be generated. (4) A set of written records is available demonstrating to the inspector that uniform and acceptable protocols have been established and are practiced in the laboratory. One short article cannot provide all the specifics for a laboratory's quality assurance program. The manufacturers and suppliers of instruments and reagents should be able to provide support in the following areas: calibration, type of controls to be used, development of a control chart, required maintenance procedures, establishment of accuracy and precision, and troubleshooting. If they cannot or will not, your laboratory should, perhaps, consider an alternative vendor to supply instrumentation and/or reagents. Additionally, resources such as the professional organizations, consultants, other clinical laboratories, and the inspectors or certifying agencies should also be considered in developing a comprehensive quality assurance program.
- 1 January 1985
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 31 (1) , 106-108
Alternative statistical approach to evaluating interlaboratory performance.
We report a new technique for realistic assessment of laboratory performance as measured by proficiency testing. Interlaboratory results accumulated from 129 participants during 18 months provide the baseline data from which we established "state-of-the-art" performance criteria for three ranges of pH, pCO2, and pO2. By concurrent use of two statistical measurement techniques, the cumulative percentile rank and the algebraic and absolute mean error, laboratories can accurately evaluate their performance in terms of acceptable state-of-the-art criteria, total error, or medical usefulness. The approach facilitates assessment of the nature of the errors that have led to inferior performance and identification of probable areas where improvement is possible. If criteria based on regulatory standards or medical usefulness goals are included, the system can provide a basis for licensure or professional quality improvement.
- 1 January 1985
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 31 (1) , 106-108
Alternative statistical approach to evaluating interlaboratory performance.
We report a new technique for realistic assessment of laboratory performance as measured by proficiency testing. Interlaboratory results accumulated from 129 participants during 18 months provide the baseline data from which we established "state-of-the-art" performance criteria for three ranges of pH, pCO2, and pO2. By concurrent use of two statistical measurement techniques, the cumulative percentile rank and the algebraic and absolute mean error, laboratories can accurately evaluate their performance in terms of acceptable state-of-the-art criteria, total error, or medical usefulness. The approach facilitates assessment of the nature of the errors that have led to inferior performance and identification of probable areas where improvement is possible. If criteria based on regulatory standards or medical usefulness goals are included, the system can provide a basis for licensure or professional quality improvement.